Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
New findings from National Cancer Institute in the area of cancer published
May 12th, 2008
According to a study from the United States, " Objective tumor response rates observed in phase II trials for metastatic melanoma have historically not provided a reliable indicator of meaningful survival benefits. To facilitate using overall survival ( OS) or progression-free survival ( PFS) as an endpoint for future phase II trials, we evaluated historical data from cooperative group phase II trials to attempt to develop benchmarks for OS and PFS as reference points for future phase II trials." "Patients and Methods Individual-level and trial-level data were obtained for patients enrolled onto 42 phase II trials ( 70 trial arms) that completed accrual in the years...
Source: Biotech Business Week (2008-05-12)
|
